Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them, rather than a periodic financial report.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It reports a specific transaction involving the acquisition of ordinary shares.
| Metric | Value |
|---|---|
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Type | Acquisition via dividend re-investment (ShareReward Plan) |
| Price per Share | £16.6373 |
| Volume | 9 shares |
| Transaction Date | July 14, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. It solely documents an initial notification of a share acquisition by Ms. E Walmsley, CEO of GSK Consumer Healthcare.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of a specific equity transaction.
Key Facts for Investor Verification
- The transaction involved the acquisition of 9 ordinary shares by Ms. E Walmsley.
- The acquisition was executed through the re-investment of dividends paid on July 14, 2016, under the Company's ShareReward Plan.
- The transaction price was £16.6373 per share.
- This filing does not contain financial performance data for the company.